|
|
Br J Cancer. 1998 August; 78(4): 546–549. | PMCID: PMC2063075 |
Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM. R. Bonacci, A. Gigliotti, E. Baudin, N. Wion-Barbot, P. Emy, M. Bonnay, A. F. Cailleux, I. Nakib, and M. Schlumberger Institut Gustave Roussy, Villejuif, France. Abstract Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (541K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med. 1981 Nov;71(5):855–875. [PubMed]
- Boven E, Vermorken JB, van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review. Cancer. 1984 Jan 1;53(1):26–29. [PubMed]
- Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, Harker WG. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1993 Jan;11(1):161–165. [PubMed]
- Chun HG, Yagoda A, Kemeny N, Watson RC. Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep. 1983 May;67(5):513–514. [PubMed]
- Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer. 1981 May 1;47(9):2153–2161. [PubMed]
- Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994 May;69(5):947–951. [PubMed]
- Hesketh PJ, McCaffrey RP, Finkel HE, Larmon SS, Griffing GT, Melby JC. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep. 1987 Feb;71(2):222–224. [PubMed]
- Hutter AM, Jr, Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med. 1966 Oct;41(4):581–592. [PubMed]
- Icard P, Louvel A, Chapuis Y. Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg. 1992 Jul–Aug;16(4):753–758. [PubMed]
- Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg. 1991 Apr;126(4):457–461. [PubMed]
- Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer. 1986 Nov 15;58(10):2198–2202. [PubMed]
- Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990 Apr 26;322(17):1195–1201. [PubMed]
- Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992 Dec;112(6):963–971. [PubMed]
- Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer. 1991 Jun 15;67(12):2997–3000. [PubMed]
- Tattersall MH, Lander H, Bain B, Stocks AE, Woods RL, Fox RM, Byrne E, Trotten JR, Roos I. Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust. 1980 May 3;1(9):419–421. [PubMed]
- van Slooten H, van Oosterom AT. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep. 1983 Apr;67(4):377–379. [PubMed]
|
